Waiting eagerly for Annual report for update on API plant. Also interest fact that Shivalik holds 39% stake in medicamen biotech which also looking to acquire company in Australia… in addition to oncology formulation plant expansion at Haridwar which will be ready this year end
Let c management commentary in annual report
Shivalik and Medicamen AR 2019 out.
Oncology and API plant should be operational by Dec 2019.
Shivalik AGM Notes, 30Sept’19
Acquired Oz trading/distribution company through Medicamen, would help in entering the market there(3-5m expected revenue by next year)
Focus on upgrading the facilities to US FDA standards
Want to shift from low margin markets(Africa & ROW) to high margin ones (US,Japan, Au’s, Europe)
Targeting to file 5 DMF by Dec-2020
Oncology unit of Medicamen and 2 blocks of dahej plant are in final stages of completion, would be operational by Dec’19
First 6-9 months of operations would mostly deal with testing, getting approvals for APIs, so API revenue wouldn’t start anytime before Q4-'21
My overall view,Management seems committed and is making lot of efforts to establish themselves as a strong API player in the market. But actual impact on financials is still some time away
Great to see Shivalik holding its ground in current market conditions. Continuous Promoter buying even after 15-20% rally seen in last month also gives lot of confidence. Promoters have raised stake by around 0.35% in last couple of months
Right Puneet, API revenues are still some time away. But they are focusing also on CRAMS for APIs and also on selling APIs for lesser regulated markets. Are you tracking this company closely, any info. on the revenue potential this year for the above ones?
This is no more a value but a growth play
Look at the below list of APIs, which Shivalik is targeting in Phase-I
| Shivalik’s API Product List | |||||
|---|---|---|---|---|---|
| Plant Validation Batches planned w.e.f. Jan 2020; Commercial quantities & Open Part of DMF by mid 2020 | |||||
| Name of Molecule | Therapeutic Category | Phase in which each molecule shall be taken up in Shivalik Rasayan Ltd | Qty in kgs exported from India (2016) | Price/kg in USD(2016 figures) | Price/kg in INR(2016 figures) |
| Azacitidine | Anti-cancer | Phase I | 458 | 19489 | 1,364,230 |
| Abiraterone Acetate | Anti-cancer | Phase I | 5500 | 4300 | 301,000 |
| Anastrozole | Anti-cancer | Phase-I | 154 | 26000 | 1,820,000 |
| Bendamustine HCl | Anti-cancer | Phase-I | 62 | 52000 | 3,640,000 |
| Bortezomib | Anti-cancer | Phase I | 11 | 1635000 | 114,450,000 |
| Busulfan | Anti-cancer | Phase-I | 21 | 149000 | 10,430,000 |
| Capecitabine | Anti-cancer | Phase-I | 115000 | 555 | 38,850 |
| Decitabine | Anti-cancer | Phase-I | 52 | 98500 | 6,895,000 |
| Erlotinib HCl | Anti-cancer | Phase-I | 2000 | 3096 | 216,720 |
| Gefitinib | Anti-cancer | Phase-I | 1770 | 2618 | 183,260 |
| Imatinib Mesylate | Anti-cancer | Phase-I | 22000 | 2213 | 154,910 |
| Lenalidomide | Anti-cancer | Phase-I | 3500000 | 3 | 210 |
| Letrozole | Anti-cancer | Phase-I | 1130 | 8673 | 607,110 |
| Melphalan HCl | Anti-cancer | Phase-I | 12 | 271034 | 18,972,380 |
| Pomalidomide | Anti-cancer | Phase-I | 47 | 27479 | 1,923,530 |
| Temozolomide | Anti-cancer | Phase-I | 950 | 14435 | 1,010,450 |
Even a fraction of Market Share will take Shivalik to the next orbit. Current PAT would grow multiple times during the next years(Starting from FY22)
Where did you get the list from?
It’s in the environmental clearance application post shared above in Sep’18. Look up.
Any reason why the stock has taken a particular beating of 9% today. Is it just becuase of the pesticide ban?
These are the APIs already in production by Shilpa Medicare. Why not buy Shilpa instead of Shivalik. Shilpa has entered into formulation too and has many USFDA approvals too.
Just before the lockdown, Medicamen Biotech advertised for a large number of fresh recruitement for their new plant.
Shivalik includes Medicamen results as well as will probably supply to Medicament when its own plant is ready but for now Medicament probably will have to source raw materials
Probably the plant is live or going just live immediately after lockdown.
The Danish company that is one of the shareholders usually supplies huge quantities to WHO
I think at the moment medicamen looks more promising over the immediate future
Positive news. Shivalik Rasayan Limited API Plant at Dahej has started taking validation batches for Oncology Products. Link
Any particular reason for 20% UC today?
What is the revenue potential of the oncology products the company is planning to manufacture? Medicamen has gotten the required license to manufacture products which will in turn affect Shivalik’s revenue positively. But to what extent?
The promoter did not sell. The reduction in the percent holding is due to preferential allotment at Rs 921 to Kim Gennerup Aps, Eric Aarestrup Sorensen and others. It can be seen that the promoter Growel Remedies is also an allottee for new shares. The number of shares has increased from approx 1.38 crores to approx 1.45 crores after the allotment (1.49 crores diluted shares).
Details:
Disclosure: Invested
